Mark D. Pegram - Publications, H-index & Citations

Mark D. Pegram

Stanford Cancer Institute

66H指数

421论文数

4.1W被引数

收录论文 118

发表时间

Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2− Advanced Breast Cancer 探究CDK4/6抑制剂在HR+/HER2−晚期乳腺癌中的真实世界证据和报告的生存结局

Oncology and Therapy

IF3.2

2025-11-14

OAAI

Sarah Sammons; Denise A. Yardley; Priyanka Sharma; Vijayakrishna K. Gadi; Mark Pegram; Purnima Pathak; Huilin Hu; Gary Sopher; Peter A. Fasching

Spontaneous upregulation of stemness and 3D spheroid formation of single cancer cells induced by scaffold-free polypeptide polyelectrolyte multilayer coating 由无支架多肽聚电解质多层涂层诱导的单个癌细胞中干性及三维球体形成的自发性上调

Biomaterials

IF12.9

2025-09-15

PREAI

Jia-Yang Chen; Chia-Chun Liu; Lucas Wang; Hang-Shiang Jiang; Pei-Syuan Lu; Curtis W. Frank; Mark D. Pegram; Chun-Jen Huang; Yi-Chun Wu; Chin-Lin Guo; Ying-Chih Chang

Breast Cancer Index (BCI) results from a HER2 low breast cancer community cohort of operable stage I-II hormone receptor positive (HR plus ) breast cancer

CANCER RESEARCH

IF16.6

2024-05-02

PREAI

Dolezal, Milana; Pegram, Mark

Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001+/- pertuzumab in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan

CANCER RESEARCH

IF16.6

2024-05-02

PREAI

Pegram, Mark; Calfa, Carmen; Chen, Chris; Salgado, Alfonso Cortes; Heeke, Arielle; Kang, Irene; Pistilli, Barbara; Pohlmann, Paula; Rugo, Hope; Saura, Cristina; Vicier, Cecile; Pearson, Cecelia I.; Tapia, Coya; Yin, Ming; Yu, Tai; Alonso, Michael N.; Perez, Edith A.; Drago, Joshua

Differential HOXB13 gene expression and promoter methylation analysis in breast cancer

CANCER RESEARCH

IF16.6

2024-05-02

PREAI

Siuliukina, Natalia; Zhang, Yi; Treuner, Kai; Pegram, Mark

Rapid and reproducible expansion of rare tumor cells: The R3CE platform for personalized medicine

CANCER RESEARCH

IF16.6

2024-04-05

PREAI

Kuo, Wen-Hung; Huang, Yen-Jang; Chen, Jia-Yang; Wu, Yi-Chun; Chen, Chia-Chun; Pegram, Mark D.; Chang, Ying-Chih

Impact of the Breast Cancer Index for Extended Endocrine Decision-Making: First Results of the Prospective BCI Registry Study

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK

IF16.4

2024-03-01

OAAI

Sanft, Tara B.; Wong, Jenna; O'Neal, Brandon; Siuliukina, Natalia; Jankowitz, Rachel C.; Pegram, Mark D.; Fox, Jenny R.; Zhang, Yi; Treuner, Kai; O'Shaughnessy, Joyce A.

Ultra-high concentration nitric oxide (UNO) enhances anti-CTLA-4 treatment activity and induces a durable anti-tumor immune response

MOLECULAR CANCER THERAPEUTICS

IF5.5

2023-12-01

PREAI

Sela, Yogev; Goldshtein, Matan; Monson, Jedidiah M.; Confino, Hila; Avniel, Amir; Pegram, Mark D.; Chaisson, Selena

Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data

NPJ BREAST CANCER

IF7.6

2023-11-17

OAAI

Lin, Nancy U.; Kumthekar, Priya; Sahebjam, Solmaz; Ibrahim, Nuhad; Fung, Anita; Cheng, Anna; Nicholas, Alan; Sussell, Jesse; Pegram, Mark

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

PREAI

Li, B. T.; Lee, K-W.; Pegram, M.; Sharma, M. R.; Lee, J.; Spira, A. I.; Kang, Y-K.; Moore, K. N.; Rasco, D.; Hanna, G. J.; Weinberg, B. A.; Yu, T.; Alonso, M.; Ptacek, J.; Yin, M.; Tapia, C.; Xu, L.; Perez, E. A.; Dumbrava, E. E.

Evolving perspectives on the treatment of HR+/HER2+metastatic breast cancer HR /HER2转移性乳腺癌治疗的发展前景

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

IF4.2

2023-08-11

OAAI

Pegram, Mark; Pietras, Richard; Dang, Chau T.; Murthy, Rashmi; Bachelot, Thomas; Janni, Wolfgang; Sharma, Priyanka; Hamilton, Erika; Saura, Cristina

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis (vol 33, pg 321, 2022)

ANNALS OF ONCOLOGY

IF65.4

2023-07-01

OAAI

Curigliano, G.; Mueller, V.; Borges, V.; Hamilton, E.; Hurvitz, S.; Loi, S.; Murthy, R.; Okines, A.; Paplomata, E.; Cameron, D.; Carey, L. A.; Gelmon, K.; Hortobagyi, G. N.; Krop, I.; Loibl, S.; Pegram, M.; Slamon, D.; Ramos, J.; Feng, W.; Winer, E.

Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer

NPJ BREAST CANCER

IF7.6

2023-06-28

OAAI

Curigliano, Giuseppe; Dent, Rebecca; Llombart-Cussac, Antonio; Pegram, Mark; Pusztai, Lajos; Turner, Nicholas; Viale, Giuseppe

Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer

NPJ BREAST CANCER

IF7.6

2023-05-31

OAAI

Pegram, Mark; Jackisch, Christian; Johnston, Stephen R. D.

Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review 人类表皮生长因子受体2阳性乳腺癌和脑转移患者的流行病学，临床结局和未满足的需求: 系统文献综述

CANCER TREATMENT REVIEWS

IF10.5

2023-04-01

PREAI

Mueller, Volkmar; Bartsch, Rupert; Lin, Nancy U.; Montemurro, Filippo; Pegram, Mark D.; Tolaney, Sara M.

Prospective assessment of the decision-making impact of the Breast Cancer Index in the BCI Registry Study

CANCER RESEARCH

IF16.6

2023-03-01

PREAI

Sanft, Tara B.; Wong, Jenna; O'Neal, Brandon; Siuliukina, Natalia; Jankowitz, Rachel C.; Pegram, Mark; Fox, Jenny; Zhang, Yi; Treuner, Kai; O'Shaughnessy, Joyce

Editorial: Metabolic Abnormalities and Breast Cancer: Challenges From Bench to Bedside

FRONTIERS IN ONCOLOGY

IF3.3

2022-04-27

OAAI

Wang, Zheng; Li, Pu; Pegram, Mark Daniel; Chen, Xiaosong

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis

ANNALS OF ONCOLOGY

IF65.4

2022-03-01

131

OAAI

Curigliano, G.; Mueller, V; Borges, V; Hamilton, E.; Hurvitz, S.; Loi, S.; Murthy, R.; Okines, A.; Paplomata, E.; Cameron, D.; Carey, L. A.; Gelmon, K.; Hortobagyi, G. N.; Krop, I; Loibl, S.; Pegram, M.; Slamon, D.; Ramos, J.; Feng, W.; Winer, E.

Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases (HER2CLIMB)

CANCER RESEARCH

IF16.6

2022-02-15

PREAI

Lin, Nancy U.; Murthy, Rashmi K.; Abramson, Vandana; Anders, Carey; Bachelot, Thomas; Bedard, Philippe; Borges, Virginia; Cameron, David; Cameron, David; Carey, Lisa; Chien, A. Jo; Curigliano, Giuseppe; DiGiovanna, Michael; Gelmon, Karen; Hortobagyi, Gabriel; Hurvitz, Sara; Krop, Ian; Loi, Sherene; Loibl, Sibylle; Mueller, Volkmar; Oliveira, Mafalda; Paplomata, Elisavet; Pegram, Mark; Slamon, Dennis; Zelnak, Amelia; Ramos, Jorge; Feng, Wentao; Winer, Eric

Final survival analysis of a phase 3 study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer

CANCER RESEARCH

IF16.6

2022-02-15

PREAI

Pivot, Xavier; Pegram, Mark D.; Cortes, Javier; Luftner, Diana; Lyman, Gary H.; Curigliano, Giuseppe; Bondarenko, Igor M.; Dvorkin, Mikhail; Ahn, Jin Hee; Im, Seock-Ah; Litwiniuk, Maria; Shparyk, Yaroslav V.; Ho, Gwo Fuang; Kislov, Nikolay V.; Wojtukiewicz, Marek; Sarosiek, Tomasz; Chae, Yee Soo; Ahn, Jin Seok; Jang, Hyerin; Kim, Sujung; Lee, Jiwon; Lee, Soo Young; Yoon, Ye Chan

研究方向